Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary nervous-system lymphoma.

S R Plotkin1, T T Batchelor

  • 1Neurology Service, Massachusetts General Hospital, Boston 02114, USA.

The Lancet. Oncology
|March 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Creation of an international registry to support discovery in schwannomatosis.

American journal of medical genetics. Part A·2016
Same author

Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.

Acta neurologica Scandinavica·2015
Same author

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

AJNR. American journal of neuroradiology·2015
Same author

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Journal of neuro-oncology·2011
Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026
Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
See all related articles

Primary nervous-system lymphoma requires different treatments than typical cancers. Methotrexate-based chemotherapy significantly improves survival and reduces side effects compared to older methods.

Area of Science:

  • Neurology
  • Oncology
  • Hematology

Background:

  • Primary nervous-system lymphoma (PNL) is a rare non-Hodgkin lymphoma confined to the nervous system.
  • PNL management differs significantly from primary brain tumors and systemic non-Hodgkin lymphoma.
  • Standard treatments like whole-brain radiotherapy have limitations, including high relapse rates and neurotoxicity.

Purpose of the Study:

  • To review the management of primary nervous-system lymphoma.
  • To highlight the efficacy of methotrexate-based chemotherapy in PNL.
  • To discuss specific PNL subtypes like leptomeningeal and intraocular lymphoma.

Main Methods:

  • Review of existing literature on primary nervous-system lymphoma treatments.
  • Comparison of radiotherapy, traditional chemotherapy, and methotrexate-based chemotherapy efficacy and toxicity.

Related Experiment Videos

  • Focus on survival rates and treatment-associated adverse effects.

    • Main Results:

    • Whole-brain radiotherapy shows high initial response rates (>90%) but is linked to significant relapse and delayed neurotoxicity.
    • First-generation chemotherapy regimens are largely ineffective due to the blood-brain barrier.
    • Methotrexate-based chemotherapy has extended median survival to over 30 months with fewer toxic effects.

    Conclusions:

    • Methotrexate-based chemotherapy represents a significant advancement in treating primary nervous-system lymphoma.
    • This approach offers improved survival outcomes and a better safety profile compared to radiotherapy alone or older chemotherapy regimens.
    • Further research into PNL, including leptomeningeal and intraocular involvement, is warranted.